The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...

The primary efficacy endpoint of the phase IIb ASPIRE study is demonstrating non-inferiority to Eylea, measured by mean change in Best Corrected Visual Acuity from baseline to the average of weeks ...